Substituted 1,2,3,3a,4,5,7,9,13,13a-decahydropyrido[1′,2′:4,5]pyrazino[1,2-a]pyrrolo[1,2-c]pyrimidines having HIV integrase inhibitory activity

Number of patents in Portfolio can not be more than 2000

United States of America

PATENT NO 11267823
APP PUB NO 20200339598A1
SERIAL NO

16924390

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Substituted 1,2,3,3a,4,5,7,9,13,13a-decahydropyrido[1′,2′:4,5]pyrazino[1,2-a]pyrrolo[1,2-c]pyrimidines having the anti-virus activity, particularly the HIV integrase inhibitory activity, and a pharmaceutical composition containing the same, particularly an anti-HIV pharmaceutical composition.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
SHIONOGI & CO LTDOKAYAMA

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Johns, Brian A Research Triangle Park, US 56 338
Kawasuji, Takashi Osaka, JP 45 683
Taishi, Teruhiko Osaka, JP 28 399
Taoda, Yoshiyuki Osaka, JP 58 784

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Sep 8, 2025
7.5 Year Payment $3600.00 $1800.00 $900.00 Sep 8, 2029
11.5 Year Payment $7400.00 $3700.00 $1850.00 Sep 8, 2033
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00